
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AMGN | NASDAQ | USD | Real-time | |
AMGN | BIVA | MXN | Delayed | |
AMGN | Mexico | MXN | Delayed | |
AAMGN | Milan | EUR | Real-time | |
AMGN | TradeGate | EUR | Delayed | |
AMGN | Frankfurt | EUR | Delayed | |
AMGN | Xetra | EUR | Delayed | |
AMGN | Buenos Aires | ARS | Delayed | |
AMGN34 | BM&FBovespa | BRL | Delayed | |
4332 | Hong Kong | HKD | Delayed | |
AMGN | Vienna | EUR | Delayed |
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Name | Age | Since | Title |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
R. Sanders Williams | 74 | 2014 | Independent Director |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Ronald D. Sugar | 74 | 2010 | Independent Director |
Greg C. Garland | 66 | 2013 | Independent Director |
Charles M. Holley | 66 | 2017 | Independent Director |
Robert A. Eckert | 69 | 2012 | Lead Independent Director |
Tyler E. Jacks | 62 | 2012 | Independent Director |
Ellen J. Kullman | 67 | 2016 | Independent Director |
S. Omar Ishrak | 67 | 2021 | Independent Director |
Brian J. Druker | 67 | 2018 | Independent Director |
Amy E. Miles | 56 | 2020 | Independent Director |
Wanda M. Austin | 69 | 2017 | Independent Director |
Michael V. Drake | - | 2022 | Independent Director |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
George Georgiou | 64 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review